Parvin Asset Management LLC bought a new position in shares of Perrigo Company plc (NYSE:PRGO – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 8,240 shares of the company’s stock, valued at approximately $212,000.
Several other institutional investors also recently bought and sold shares of the business. Headlands Technologies LLC lifted its stake in shares of Perrigo by 1,942.0% during the fourth quarter. Headlands Technologies LLC now owns 1,409 shares of the company’s stock worth $36,000 after buying an additional 1,340 shares during the period. Versant Capital Management Inc purchased a new stake in Perrigo in the fourth quarter valued at $45,000. GAMMA Investing LLC raised its holdings in shares of Perrigo by 93.7% in the 4th quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock valued at $49,000 after buying an additional 929 shares during the period. Central Pacific Bank Trust Division grew its stake in Perrigo by 33.3% during the 4th quarter. Central Pacific Bank Trust Division now owns 2,000 shares of the company’s stock worth $51,000 after purchasing an additional 500 shares in the last quarter. Finally, Venturi Wealth Management LLC boosted its position in shares of Perrigo by 97.8% during the 4th quarter. Venturi Wealth Management LLC now owns 4,215 shares of the company’s stock worth $108,000 after acquiring an additional 2,084 shares in the last quarter. 95.91% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Perrigo
In other Perrigo news, EVP Ronald Craig Janish sold 7,800 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $27.44, for a total value of $214,032.00. Following the completion of the sale, the executive vice president now owns 33,666 shares of the company’s stock, valued at $923,795.04. The trade was a 18.81 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.70% of the company’s stock.
Perrigo Price Performance
Perrigo (NYSE:PRGO – Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.01. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.20 billion. Research analysts anticipate that Perrigo Company plc will post 2.56 EPS for the current year.
Perrigo Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 25th. Investors of record on Friday, March 7th were given a $0.29 dividend. The ex-dividend date was Friday, March 7th. This is a positive change from Perrigo’s previous quarterly dividend of $0.28. This represents a $1.16 annualized dividend and a dividend yield of 4.53%. Perrigo’s payout ratio is currently -92.80%.
Analyst Upgrades and Downgrades
Several equities analysts have issued reports on the stock. Argus cut shares of Perrigo from a “buy” rating to a “hold” rating in a research note on Tuesday, January 14th. Piper Sandler lowered shares of Perrigo from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $34.00 to $27.00 in a report on Monday, January 6th. Finally, StockNews.com downgraded shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $33.00.
Check Out Our Latest Analysis on PRGO
Perrigo Company Profile
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Featured Stories
- Five stocks we like better than Perrigo
- What Are Dividends? Buy the Best Dividend Stocks
- The 5 Top Buys for May: Strong Signals at Critical Support Levels
- How to Invest in Biotech Stocks
- Joby Aviation Shares Eye Breakout After Transition Flight Win
- What is MarketRank� How to Use it
- NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone
Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company plc (NYSE:PRGO – Free Report).
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.